Biogen (NASDAQ: BIIB) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both biopharmaceuticals companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings for Biogen and Syndax Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 0 10 16 1 2.67
Syndax Pharmaceuticals 0 0 9 0 3.00

Biogen currently has a consensus price target of $341.96, suggesting a potential upside of 8.86%. Syndax Pharmaceuticals has a consensus price target of $24.29, suggesting a potential upside of 112.10%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Biogen.

Volatility and Risk

Biogen has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 4.43, meaning that its share price is 343% more volatile than the S&P 500.


This table compares Biogen and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 29.44% 38.51% 20.80%
Syndax Pharmaceuticals -4,294.59% -58.23% -45.65%

Institutional & Insider Ownership

87.7% of Biogen shares are held by institutional investors. Comparatively, 64.3% of Syndax Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 24.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Biogen and Syndax Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Biogen $11.45 billion 5.80 $3.70 billion $16.31 19.26
Syndax Pharmaceuticals $1.22 million 228.91 -$44.47 million ($2.84) -4.03

Biogen has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.


Biogen beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company‚Äôs product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with's FREE daily email newsletter.